Physician profile
Robert Schreiman
NPI 1871605196
$5,557.66
in general payments reported to CMS, 2019-2025
44 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $370 · 2021: $693 · 2022: $933 · 2023: $1,466 · 2024: $1,106 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,931.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $1,238.32 | 2021-2025 | Nuplazid |
| Avanir Pharmaceuticals, INC. | $453.31 | 2019-2022 | |
| Sk Life Science, INC. | $417.05 | 2022-2025 | |
| Cmp Pharma, INC. | $397.76 | 2020-2023 | Norliqva, Carospir, Tadliq |
| Teva Pharmaceuticals USA, INC. | $335.50 | 2022-2025 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $295.05 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $278.09 | 2022-2025 | |
| Astellas Pharma US INC | $260.20 | 2019-2021 | |
| Lilly USA, LLC | $179.78 | 2020-2025 | Amyvid, Zepbound, Trulicity |
| Medtronic, INC. | $159.69 | 2023 | Abre |
| Novartis Pharmaceuticals Corporation | $156.59 | 2019-2023 | |
| Alkermes, INC. | $124.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.70 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $98.79 | 2019-2021 | |
| Glaxosmithkline, LLC. | $74.99 | 2019-2023 | Arexvy |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $69.34 | 2020-2023 | Verquvo, Steglatro, Belsomra |
| Pfizer INC. | $67.65 | 2023-2024 | |
| Lundbeck LLC | $64.69 | 2023-2024 | Rexulti |
| Inari Medical, INC. | $62.31 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novo Nordisk INC | $60.51 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $59.89 | 2022-2024 | Airsupra, Farxiga |
| Eisai INC. | $55.78 | 2020-2024 | |
| Sun Pharmaceutical Industries INC. | $43.37 | 2021 | |
| Radius Health, INC. | $42.75 | 2024 | Tymlos |
| Scilex Pharmaceuticals INC. | $40.86 | 2023-2024 | Ztlido |
| Abbvie INC. | $36.54 | 2022-2025 | |
| Amarin Pharma, INC. | $35.00 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $34.04 | 2023-2024 | Gemtesa |
| Biogen, INC. | $31.07 | 2021 | |
| Indivior INC. | $28.02 | 2024 | Perseris |
| Mylan Specialty L.P. | $24.67 | 2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $24.48 | 2019 | |
| Alvogen INC | $24.22 | 2025 | Teriparatide |
| Allergan, INC. | $20.91 | 2020 | |
| Urovant Sciences INC | $20.48 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.38 | 2025 | Caplyta |
| Amgen INC. | $20.06 | 2025 | Repatha |
| Corcept Therapeutics | $19.73 | 2024 | Korlym |
| Hologic Sales and Service, LLC | $19.01 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.82 | 2020 | |
| Vanda Pharmaceuticals INC. | $13.31 | 2024 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $10.96 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schreiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.